Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
Um, but those are the big ones
Questions about which program tier is right for you
Patient portal friction appears in a handful of reviews
CHAMPVA does not cover GLP-1 for weight loss at all
Novo Nordisk's investigational once-weekly Zenagamtide, the first GLP-1 and amylin dual receptor agonist in a single molecule, delivered up to 1.71% HbA1c reduction and up to 14.6% body weight loss in a Phase 2 trial of 262 adults with type 2 diabetes at ADA 2026
US$ 25.61
US$ 24.85
US$ 24.01
